HPV vaccine

HOOKIPA Pharma’s LCMV-based Immunotherapy for HPV16+ Cancers Demonstrates High Immunogenicity, According to Peer Reviewed Article

Retrieved on: 
Wednesday, September 16, 2020

It is currently in Phase 1/2 clinical trials (NCT04180215) for HPV16+ cancers alone and in combination with an approved checkpoint inhibitor.

Key Points: 
  • It is currently in Phase 1/2 clinical trials (NCT04180215) for HPV16+ cancers alone and in combination with an approved checkpoint inhibitor.
  • HPV-associated cancers, especially head and neck cancers, remain a significant health concern, as no curative therapies are currently available.
  • Human Papillomavirus, or HPV, is estimated to cause about 5% of the worldwide burden of cancers.
  • This includes approximately 99% of cases in cervical, up to 60% of head and neck, 70% of vaginal and 88% of anal cancers.

Public flu shots offered Sept. 25 – 27, 9 am – 3 pm, at the Minnesota State Fair grounds

Retrieved on: 
Monday, September 14, 2020

Flu shots will be administered by nurses with Hennepin Healthcares Worksite Wellness program.

Key Points: 
  • Flu shots will be administered by nurses with Hennepin Healthcares Worksite Wellness program.
  • Two types of flu vaccine are available: Quadrivalent vaccine for people between 6 months-64 years and High Dose vaccine for people age 65 and older.
  • If someone is uninsured, they will receive a free flu shot through the MnVFC (Minnesota Vaccine for Children) or UUAV (Uninsured and Underinsured Adult Vaccine) state program.
  • Health Fair 11s Flu Fighter Clinics are made possible with additional support from Hennepin Healthcare and the Minnesota State Fair.

New Research Suggests How to Message the Eventual COVID-19 Vaccine in the US

Retrieved on: 
Wednesday, September 9, 2020

Highlighting the story of an individual who was impacted by COVID-19 was, by far, the most effective message theme.

Key Points: 
  • Highlighting the story of an individual who was impacted by COVID-19 was, by far, the most effective message theme.
  • The HPV research also found that a message about vaccine safety is ineffective, despite people reporting "safety" as the biggest concern about vaccination.
  • Although personal stories were effective for both flu and COVID-19 vaccine messaging, the "community" theme was most persuasive in the flu research , but ineffective for the COVID vaccine.
  • This reinforces that we can't repurpose flu vaccine marketing messages for the eventual COVID vaccine.

Vaxart, Inc. to Participate in September Virtual Investor Conferences

Retrieved on: 
Thursday, September 3, 2020

A link to the webcasts along with a replay of the webcasts will be accessible on the Events & Presentations page of the Investors section on the Companys website.

Key Points: 
  • A link to the webcasts along with a replay of the webcasts will be accessible on the Events & Presentations page of the Investors section on the Companys website.
  • Vaxart is a clinical-stage biotechnology company focused on developing oral tablet vaccines designed to generate mucosal and systemic immune responses that protect against a wide range of infectious diseases and has the potential to provide sterilizing immunity for diseases such as COVID-19.
  • Vaxarts development programs include oral tablet vaccines that are designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV).
  • For more information, please visit www.vaxart.com.

WebMD Poll: More than half will get Covid-19 vaccine in first year, 42% in first six months

Retrieved on: 
Wednesday, September 2, 2020

Fewer than one-third say they will get the vaccine in the first three months, which is consistent in both polls.

Key Points: 
  • Fewer than one-third say they will get the vaccine in the first three months, which is consistent in both polls.
  • In the new poll, about 12% said they will not get a vaccine at all, and the rest remain unsure.
  • Vaccine efficacy rates range from about 40% to 60% for the seasonal flu vaccine, to 97% for the measles, mumps and rubella vaccine, according to CDC data .
  • "Understanding how well the vaccine works could be a hurdle for patients," said John Whyte, MD, chief medical officer of WebMD.

Russia Registers First COVID-19 Vaccine - ResearchAndMarkets.com

Retrieved on: 
Friday, August 14, 2020

Russia has today become the first country to register a COVID-19 vaccine.

Key Points: 
  • Russia has today become the first country to register a COVID-19 vaccine.
  • In July, the World Health Organization reported that there were 26 vaccine candidates in the clinical evaluation stage including the vaccine registered in Russia.
  • The Russian Health Ministry intends to offer the vaccine first to healthcare workers, teachers and other high risk groups.
  • Mass production of the vaccine is set to begin in September with a mass vaccination drive planned for October.

China Human Vaccine Market Insights 2020-2026 Featuring In-Depth Profiles of 22 Companies

Retrieved on: 
Friday, August 7, 2020

DUBLIN, Aug. 7, 2020 /PRNewswire/ -- The "China Human Vaccine Industry Report, 2020-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 7, 2020 /PRNewswire/ -- The "China Human Vaccine Industry Report, 2020-2026" report has been added to ResearchAndMarkets.com's offering.
  • Human vaccine industry in China (environments, status quo, market demand, market size, import & export, competition pattern);
    Human vaccine market segments in China (market demand, lot releases, competitive landscape);
    22 human vaccine companies (operation, vaccine business, etc.)
  • The Chinese human vaccine market is now occupied by local companies, where the state-owned enterprises command more than a half of the market.
  • Although the Chinese human vaccine market is ruled by local companies, the imported vaccines are largely the extra EPI vaccines (not free, and residents can choose whether they want to be inoculated) such as 13-valent pneumonia vaccine, HPV vaccine and DTaP-IPV/Hib vaccine.

Insights on the Human Papillomavirus Vaccine Worldwide Industry to 2025 - North America is Expected to Hold Largest Market Share - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 5, 2020

Ltd.

Key Points: 
  • Ltd.
    Nearly all instances of cervical cancer are caused by human papillomavirus (HPV).
  • Also, there are highly sensitive and specific molecular tests now available to identify from DNA, the high-risk HPV types, in cervical cancer screening.
  • Thus, owing to the rising cases of cervical cancer the market is expected to witness high growth over the forecast period.
  • The United States is expected to be the largest HPV vaccine market owing to the presence of better healthcare infrastructure.

The American Cancer Society Campaign Aims to Increase HPV Vaccination During Pandemic

Retrieved on: 
Monday, August 3, 2020

ATLANTA, Aug. 3, 2020 /PRNewswire/ --In an effort to boost public health and help keep vaccinations on track in the midst of the coronavirus pandemic, the American Cancer Society is renewing Mission: HPV Cancer Free , a campaign to eliminate HPV cancers as a public health problem, starting with cervical cancer.

Key Points: 
  • ATLANTA, Aug. 3, 2020 /PRNewswire/ --In an effort to boost public health and help keep vaccinations on track in the midst of the coronavirus pandemic, the American Cancer Society is renewing Mission: HPV Cancer Free , a campaign to eliminate HPV cancers as a public health problem, starting with cervical cancer.
  • "HPV vaccination offers the very rare opportunity to help prevent not just one but six types of cancer.
  • Just two doses of this vaccine, given to kids at age 9-12, can prevent over 90% of HPV cancers," said Debbie Saslow, PhD., managing director, HPV & GYN Cancers for the American Cancer Society.
  • HPV vaccination helps protect girls from cancers of the cervix, throat, vagina, vulva, and anus later in life
    The goal of Mission: HPV Cancer Free is to reach a vaccination rate of 80% of 13-year-olds in the United States by 2026.

World's 1st inactivated COVID-19 vaccine produces antibodies

Retrieved on: 
Wednesday, June 24, 2020

People who received two doses of the vaccine at an interval of 28 days, saw their neutralizing antibody positive conversion rate reach 100%.

Key Points: 
  • People who received two doses of the vaccine at an interval of 28 days, saw their neutralizing antibody positive conversion rate reach 100%.
  • According to CNBG, the Phase I/II clinical trials were randomized, double-blind, placebo-controlled clinical studies.
  • On April 12, the vaccine obtained the world's first clinical trial approval, and Phase I/II clinical trials were then launched in Wuzhi county of Henan province.
  • The data presented research results on different ages, different procedures, different doses, and different injection times in a relatively comprehensive manner.